Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
Abstract: Methods and compositions for treating and alleviating symptoms of irradiation injuries, therapeutic radiation intervention and/or anti-cancer therapies in a subject via pulmonary airway administration of granulocyte macrophage colony stimulating factor (GM-CSF) or a compound with similar affinity to the specific alveolar GM-CSF receptor to enhance pulmonary host defense are provided.
Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
December 26, 2017
Assignee:
Glaxo Group Limited
Inventors:
Andrew Beaton, Caroline Dimech, Peter Franz Ertl, Susannah Karen Ford, Ruth Mcadam
Abstract: A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.
Type:
Grant
Filed:
November 25, 2014
Date of Patent:
December 12, 2017
Assignee:
Idogen AB
Inventors:
Leif Salford, Hans Olov Sjogren, Bengt Widegren
Abstract: Binding proteins that bind one or more of VEGF, PDGF and/or their receptors, including antibodies, CDR-grafted antibodies, humanized antibodies, binding fragments, fusion proteins, and bispecific or multispecific proteins thereof are disclosed. Also disclosed are methods of making and using the binding proteins.
Type:
Grant
Filed:
June 15, 2016
Date of Patent:
December 12, 2017
Assignee:
AbbVie Inc.
Inventors:
Jijie Gu, Diana Bowley, Lucia Eaton, Feng Dong, Lorenzo Benatuil, Tariq Ghayur, Ravi Chari, Matthew Rieser, Anca Clabbers
Abstract: The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.
Type:
Grant
Filed:
May 19, 2015
Date of Patent:
November 14, 2017
Assignee:
The Regents of the University of California
Inventors:
Charles Zuker, Jon E. Adler, Nick Ryba, Ken Mueller, Mark Hoon
Abstract: An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
November 14, 2017
Assignees:
Rhode Island Council on Postsecondary Education (Statutory Successor to Rhode Island Board of Governors for Higher Education), Yale University
Inventors:
Yana K. Reshetnyak, Oleg A. Andreev, Donald M. Engelman
Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
Type:
Grant
Filed:
February 16, 2016
Date of Patent:
November 7, 2017
Assignee:
ACCLERON PHARMA INC.
Inventors:
Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
Abstract: Administration of an antibody that specifically binds IL-1? is useful for treating cachexia and increasing the lifespan of a subject suffering from cachexia.
Abstract: The disclosure provides compositions and methods related to the diagnosis, prognosis, and treatment of inflammatory diseases and disorders, especially allergic inflammatory diseases and disorders.
Abstract: The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits VEGF-B signalling.
Abstract: Provided are methods and systems for determining functional relationships between ex vivo skin models and an inflammatory skin condition. Also provided are methods and systems for identifying modulators of inflammation of skin, as well as the use of modulators identified by such methods or systems for the preparation of cosmetic compositions, personal care products, or both.
Type:
Grant
Filed:
August 15, 2013
Date of Patent:
October 31, 2017
Assignee:
The Procter & Gamble Company
Inventors:
Deborah Ruth Finlay, Kevin John Mills, Charles Carson Bascom
Abstract: Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.
Type:
Grant
Filed:
September 5, 2014
Date of Patent:
October 31, 2017
Assignee:
MESO SCALE TECHNOLOGIES, LLC
Inventors:
Jeff D. Debad, Eli N. Glezer, Sudeep M. Kumar
Abstract: The present invention provides, among other things, dimeric multispecific binding agents (e.g., fusion proteins comprising antibody components) that have improved properties over multispecific binding agents without the capability of dimerization.
Abstract: Disclosed is a Tat protein, the amino acid sequence of which is shown as SEQ NO: 1, SEQ NO: 2, SEQ NO: 3 and SEQ NO: 4. The Tat protein of the present invention has been studied and developed and can be a Latent infection of HIV-1 activating potential drug.
Abstract: A mechanism is provided for utilizing a nanodevice to distinguish molecules with different structure. The molecules translocate through or across a nanochannel filled with a electrolyte solution. An electrical signal through the nanochannel is measured for every translocation event. Inner surfaces of the nanochannel include a functional layer, which is a coating to functionalize the nanochannel, in which the functional layer is configured to interact with predetermined ones of the molecules during translocation events. It is determined that a combination of at least two different molecules is formed based on predetermined ones of the molecules interacting with the functional layer to change the electrical signal and/or change a translocation time for the translocation event.
Type:
Grant
Filed:
December 26, 2012
Date of Patent:
October 17, 2017
Assignees:
INTERNATIONAL BUSINESS MACHINES CORPORATION, THE UNIVERSITY OF MELBOURNE, FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
Inventors:
Matthew Downton, Natalie Gunn, Stefan Harrer, Priscilla Rogers, John Wagner, Ross Bathgate, Daniel Scott, Stan Skafidas
Abstract: There is disclosed compositions and methods relating to or derived from anti-CXCR5 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR5, CXCR5-binding fragments and derivatives of such antibodies, and CXCR5-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR5 related disorders or conditions, including various inflammatory disorders and various cancers.
Type:
Grant
Filed:
August 12, 2015
Date of Patent:
September 19, 2017
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Dingqiu Huang, Barbara A. Swanson, Heyue Zhou
Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
Type:
Grant
Filed:
September 8, 2014
Date of Patent:
September 19, 2017
Assignee:
GENZYME CORPORATION
Inventors:
Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
Abstract: There is disclosed compositions and methods relating to or derived from anti-CXCR3 antibodies. More specifically, there is disclosed fully human antibodies that bind CXCR3, CXCR3-binding fragments and derivatives of such antibodies, and CXCR3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having CXCR3 related disorders or conditions, including various inflammatory disorders and various cancers.
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
September 19, 2017
Assignee:
Sorrento Therapeutics, Inc.
Inventors:
Barbara A. Swanson, Dingqiu Huang, Heyue Zhou
Abstract: Acellular compositions for treating inflammation, comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII. Components of the acellular compositions may be derived from biologic materials, such as blood clots and urine. Components may also be obtained from cell cultures.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
September 12, 2017
Assignee:
Biomet Biologics, LLC
Inventors:
Jennifer E. Woodell-May, Joel C. Higgins, Michael D. Leach, Krista O'Shaughnessey